Showing 106 of 106on this page. Filters & sort apply to loaded results; URL updates for sharing.106 of 106 on this page
ACELYRIN logo in transparent PNG and vectorized SVG formats
ACELYRIN Merger with Alumis Approved, Forms Major Immunology Biopharma ...
Acelyrin & Intersect update - Intersect Management
Acelyrin announces phase 2 data and phase 3 design for TED therapy
Acelyrin Raises $540M In IPO, Stock Gains Over 20% In Trading Debut
Alumis and Acelyrin sign agreement to merge
Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo ...
Immune drugmakers Alumis and Acelyrin to merge | BioPharma Dive
Alumis and ACELYRIN Announce Amended Merger Agreement
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset
Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake ...
Alumis and ACELYRIN Announce Definitive Merger Agreement, Creating a ...
Q&A: Acelyrin CEO Shao-Lee Lin details immunology biotech’s $540M IPO ...
Acelyrin sets hopes high for arthritis drug with $300M fundraise ...
Affibody’s Partner ACELYRIN Announces Positive Top-line Results for ...
Alumis & ACELYRIN Merge to Advance Therapies for Immune Diseases
ACELYRIN acquires ValenzaBio, strengthens immunology position ...
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma ...
Acelyrin follows Kenvue with largest IPO for a biotech startup since ...
Acelyrin prices $540M IPO – fifth largest in biopharma history | BioWorld
Acelyrin (SLRN) is Exploding in 2025 – Is SLRN the Hottest Biotech Play ...
ACELYRIN Salaries | Levels.fyi
ACELYRIN to Present Phase 2 Data & Phase 3 Design for Lonigutamab Online
Acelyrin eye drug heads to late-stage testing after trial win ...
Strategic overhaul at Acelyrin after late-stage success | Biotechnology ...
Acelyrin files IPO – is a biotech comeback on the way? | pharmaphorum
Acelyrin IPO: Investment Opportunities & Pre-IPO Valuations - Forge
ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous ...
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study | Nasdaq
Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal ...
Acelyrin unveils phase 3 program design for lonigutamab in thyroid eye ...
Acelyrin (SLRN) IPO deck
Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage ...
ACELYRIN Scores $250 Million to Progress Innovative Antibody Mimetic ...
Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal - WSJ
Alumis (ALMS) Merges with ACELYRIN
ACELYRIN Confirms Merger Plans Despite Interest from Rival - Investors ...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of ...
Alumis Completes ACELYRIN Merger, Extends Cash Runway Into 2027 ...
Acelyrin (SLRN) to Post Quarterly Earnings on Tuesday - American ...
Buy ACELYRIN Inc Stock - SLRN Stock Price Today & News - Public.com
ACELYRIN acquires ValenzaBio, strengthens immunology position
Acelyrin 8K Regulation FD Disclosure | SLRN 6 Mar 25 | 99.1
5.4亿美元：两年来最大规模的生物医药IPO诞生 5月5日， Biotech 公司 Acelyrin (NASDAQ:SLRN)在纳斯达克交易 ...
Mina Kim - Chief Legal & Administrative Officer at ACELYRIN | The Org
Acelyrin reports Ph1/2 data on potential Tepezza competitor in thyroid ...
November 16 2021
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent ...
Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers ...
Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from ...
Horizon alums unveil Acelyrin, a biotech to accelerate the development ...
What Acelyrin's Massive IPO Means for the Future of Biotech - dot.LA
Alumis and Acelyrin: Exploring Reverse Mergers Ahead of IPOs in ...
Biopharma Digital Marketing Strategy | Arcsec Digital
Top 10 Startups in Los Angeles
生物技术公司Acelyrin上市：市值超20亿美元 路演PPT曝光 - 知乎
Acelepryn Active Ingredient Unveiled: A Breakthrough In Insect Control ...
Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis ...
Alumis Inc. (ALMS) Stock Price, News, Quote & History - Yahoo Finance
生物技术公司Acelyrin上市：市值超20亿美元 路演PPT曝光_腾讯新闻
Acelyrin, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ ...
5月生物医药上市盘点：两年来最大规模的Biotech IPO诞生 - 知乎
Alumis Inc. Completes Merger with ACELYRIN, Boosts Balance Sheet and ...
The Revised Alumis-ACELYRIN Merger: A Strategic Rebalance for Biotech ...
Labtician Launches Lab TRIACTIV Artificial Tears | OBN
News | Westlake Village Biopartners
Biotech IPOs in 2023: Shaping the Future of Innovation - Xtalks
Acelyrin-2023-05-04 | Piper Sandler
Cision - MediaStudio View Media
ACELYRIN完成2.5亿美元B轮融资，宣布Izokibep获批_公司
ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Announce ...
这11家生物技术公司获得了2022年最高融资，你知道几个？ - 知乎
Izokibep治疗化脓性汗腺炎3期试验取得积极结果——药研快讯
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis ...
Our Clients | Precision AQ
SPONSORS – CROS – NeoClinical
